Karin Hehenberger

Karin M.
Hehenberger was the founder of Lyfebulb LLC, founded in 2014, where the title held was Chief Executive Officer & Director.
Dr. Hehenberger is also the founder of Lyfebulb Holdings, Inc...
Current jobs include Independent Director at Diamyd Medical AB since 2021, Director at Amal Therapeutics SA, Director at Aadi Subsidiary, Inc., Director at Rolf Lufts Stiftelse Foer Diabetesforskning since 2004, Director at AnaCardio AB since 2022, and Chief Medical Officer at Diabetic Care Rx LLC.
Former jobs include Senior Director-Scientific Communications at Oldtech, Inc., Director at Lighthouse International, Independent Director at Whitehawk Therapeutics, Inc. from 2021 to 2025, Director at Newron Sweden AB, Partner & Investment Director at Scandinavian Life Science Ventures AB from 2005 to 2008, Director at Atlas Antibodies AB, Director at American Diabetes Association, VP-Metabolics Strategy & Business Development at Johnson & Johnson, Executive Vice President-Scientific Affairs at Fortress Biotech, Inc. in 2013, Consultant at McKinsey & Co., Inc., Senior Vice President-Strategic Alliances at JDRF International, Post-Doctoral Fellow at Joslin Diabetes Center, Inc., and SVP-Medical Affairs & Corporate Communications at Immune Pharmaceuticals, Inc. Education includes a doctorate from Karolinska Institutet.